Ravi Chari
10Patents
5h-index
31Co-inventors
66Inventor score
Filing activity: Jul 13, 1992 → Jun 15, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5208020A | Cytotoxic agents comprising maytansinoids and their therapeutic use | Emerging Cross-Sectional Technologies | 747 | Expired |
| US5416064A | Cytotoxic agents comprising maytansinoids and their therapeutic use | Emerging Cross-Sectional Technologies | 487 | Expired |
| US9670276B2 | IL-1 binding proteins | Chemistry; Metallurgy | 15 | Active |
| US9045551B2 | Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof | Chemistry; Metallurgy | 11 | Active |
| US9163093B2 | Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US9505829B2 | Anti-NGF antibodies and their use | Chemistry; Metallurgy | 4 | Active |
| US9944720B2 | Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof | Chemistry; Metallurgy | 4 | Active |
| US9840554B2 | Antibodies against platelet-derived growth factor (PDGF) | Chemistry; Metallurgy | 1 | Active |
| US10125192B2 | Caninized anti-NGF antibodies and their use | Chemistry; Metallurgy | 0 | Active |
| US10093725B2 | Anti-NGF antibodies and their use | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.